ArticleThe Journal of infectious diseases2016
Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Review
- Influenza A Virus Nucleoprotein Activates the JNK Stress-Signaling Pathway for Viral Replication by Sequestering Host Filamin A Protein.Frontiers in microbiology · 2020Article
- Article
- Norovirus antivirals: Where are we now?Medicinal research reviews · 2019Review
- TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.Antimicrobial agents and chemotherapy · 2018Article
- Norovirus Illnesses in Children and Adolescents.Infectious disease clinics of North America · 2018Review
- Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.Viruses · 2018Article
- Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.Antimicrobial agents and chemotherapy · 2017Article
- Structure-based exploration and exploitation of the SEuropean journal of medicinal chemistry · 2017Article
- Recent advances in understanding noroviruses.F1000Research · 2017Review
- Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.Antiviral research · 2016Review
- Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model.Antiviral research · 2016Article
- Norovirus in 2016-Emesis Aplenty but Clear Signs of Progress.The Journal of infectious diseases · 2016Article
- Article
- Norovirus disease among older adults.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.